drugset / Trial / NCT07081022

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

NCT07081022

Phase 2 Recruiting 180 enrolled Shanghai Junshi Bioscience Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma

Timeline

Start
2025-08-17
Primary completion
2027-04-06
Completion
2027-04-06

Drugs

EvaluationDrugModalityDoseRoute
Subject JS203 Unknown
Background Carboplatin Small molecule
Background Cyclophosphamide Other / unclassified
Background Doxorubicin Other / unclassified
Background Etoposide Small molecule
Background Gemcitabine Small molecule
Background Ifosfamide Small molecule
Background Lenalidomide Other / unclassified
Background Oxaliplatin Small molecule
Background Prednisone Other / unclassified
Background Rituximab Monoclonal antibody
Background Vincristine Small molecule